Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IDM Pharma Inc.

Division of Takeda Pharmaceutical Co. Ltd.

Latest From IDM Pharma Inc.

Sucampo Adds New Member To Board

Sucampo Pharmaceuticals, Inc. has named Timothy P. Walbert to its board of directors. Currently, Walbert is chair, president and CEO of Horizon Pharma Plc. and prior to this he was CEO, president and director of IDM Pharma, Inc. which was acquired by Takeda. Walbert has also previously served as executive vice-president of commercial operations at NeoPharm, Inc.


PhRMA names Horizon CEO board member

Timothy P Walbert, chair, president and CEO of Horizon Pharma, has been named a member of the board of directors for the Pharmaceutical Research and Manufacturers of America (PhRMA). PhRMA represents the country's leading biopharmaceutical research and biotechnology companies, and is devoted to advancing public policies in the US and around the world that support innovative medical research. Mr Walbert joined Horizon Pharma in 2008 as president and CEO, and has served as chair of the company's board of directors since 2010. Prior to joining Horizon, Mr Walbert was president, CEO and director of IDM Pharma, a public biopharmaceutical company acquired by Takeda in June 2009.

Stockwatch: Fifty shades of fail

While stock market analysts ponder the reasons for the current low volatility of broad market stock indices like the S&P500 and rising stock prices, against the backdrop of what the bond market suggests will be a partial dissolution of the Euro, investors in some biotechnology stocks do not seem to be asking any questions before parting with their money.

Infectious Diseases Cancer

Commentary: Is Amgen exploiting poor European immigrants?

Amgen, it appears, likes to exploit European immigrants as a shield against poor financial performance.

Infectious Diseases Cancer
See All

Company Information